Zentalis Pharmaceuticals, Inc.

ZNTL

Zentalis Pharmaceuticals, Inc.

ZNTL

Insider Sentiment (TTM):

Last Purchase:2025-12-31Last Sale:2026-02-10Shares Purchased (TTM):6,459,973Shares Sold (TTM):7,508,674

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:39,894,587Shares Outstanding:70,264,000Institutional Ownership Pct.:56.78%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	25	32	36	39	38	42	34	41	37	38	28	111
Available For Sale Securities Debt Securities	-	-	-	-	-	-	-	-	-	-	455	406
Investments	-	-	-	-	-	-	-	350	389	451	-	-
Available For Sale Securities Debt Securities Curr…	150	180	210	239	249	278	318	-	-	-	455	-
Equity Securities Fv Ni	-	-	0	2	17	12	19	-	-	-	0	-
Accounts Receivable Net Current	-	-	0	0	0	0	5	-	-	-	0	-
Prepaid Expense And Other Assets Current	7	6	7	8	8	10	10	9	13	15	14	12
Assets Current	181	218	253	288	312	343	386	400	440	504	497	528
Property Plant And Equipment Net	3	3	3	3	3	3	5	5	5	6	6	6
Operating Lease Right Of Use Asset	25	26	26	30	31	32	33	33	33	35	36	36
Prepaid Expense And Other Assets Noncurrent	4	4	4	3	3	3	4	6	7	7	7	9
Equity Method Investments	-	-	-	-	-	-	-	-	-	-	0	0
Goodwill	-	-	-	-	-	-	0	4	4	4	4	4
Restricted Cash Noncurrent	3	3	3	3	3	3	3	3	3	3	3	3
Assets	215	253	289	327	352	384	430	451	492	557	552	586
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	7	7	7	4	8	7	8	20	11	15	14
Accrued Liabilities Current	29	28	29	30	35	42	45	47	46	44	54	45
Liabilities Current	38	35	37	37	39	49	53	55	67	55	69	59
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	-	-	-	-	0	0
Operating Lease Liability Noncurrent	34	35	36	37	38	39	40	40	41	43	43	43
Other Liabilities Noncurrent	1	1	1	1	1	1	1	1	1	1	2	2
Liabilities	72	70	73	74	77	89	93	96	109	99	114	104
Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,413	1,409	1,407	1,409	1,404	1,398	1,391	1,360	1,349	1,336	1,324	1,310
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	0	0	1	2	0	1	2	-0
Retained Earnings Accumulated Deficit	-1,269	-1,227	-1,191	-1,156	-1,130	-1,103	-1,054	-1,007	-967	-878	-889	-828
Stockholders Equity	144	183	216	253	274	295	337	354	383	459	437	482
Liabilities And Stockholders Equity	215	253	289	327	352	384	430	451	492	557	552	586
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Minority Interest	-	-	-	-	-	-	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	72	71	69	72	72	72	71	71	71	71	71	71
Shares Outstanding	72	71	69	72	72	72	71	71	71	71	71	71

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-14.49%	4.21%	10.75%	-	-	-	-	-	-	-	-	-
2025	27.73%	5.88%	12.61%	22.46%	12.32%	23.91%	5.30%	3.79%	84.09%	73.78%	51.69%	40.45%
2024	-3.49%	-66.77%	-63.69%	15.67%	25.00%	-5.67%	-5.66%	-12.67%	-53.10%	-26.70%	-28.41%	-23.86%
2023	-	-	-	6.10%	-21.58%	-36.67%	-9.13%	21.39%	1.60%	-7.21%	-11.90%	-17.95%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.82	6.19	6.93	7.76	7.99	6.94	7.32	7.29	6.59	9.19	7.16	8.97
Quick Ratio	4.64	6.01	6.73	7.55	7.78	6.73	7.13	7.13	6.39	8.92	6.96	8.77
Working Capital	143.65M	182.86M	216.63M	251.13M	272.57M	293.45M	333.34M	345.39M	372.92M	449.01M	427.35M	469.35M
Leverage & Debt
Debt to Equity	0.50	0.39	0.34	0.29	0.28	0.30	0.28	0.27	0.29	0.22	0.26	0.22
Debt Ratio	0.33	0.28	0.25	0.23	0.22	0.23	0.22	0.21	0.22	0.18	0.21	0.18
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.07	0.06	0.06	0.14	0.08	0.07	0.08	0.00	0.00
Days Sales Outstanding TTM	-	-	-	-	-	-	27.07	-	-	-	-	-
Receivables Turnover TTM	-	-	-	-	-	-	13.49	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.96	-1.77	-1.91	-2.07	-2.26	-3.13	-2.33	-2.52	-2.74	-3.08	-4.47	-4.05
Free Cash Flow Per Share TTM	-1.79	-1.79	-1.74	-2.13	-2.37	-2.12	-2.41	-1.20	-1.62	-2.98	-3.19	-2.90
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-615.16%	-681.04%	-789.32%	-283.57%	-515.94%	-543.77%	-639.35%	-	-
Net Profit Margin TTM	-	-	-	-555.91%	-606.03%	-834.60%	-246.00%	-442.08%	-480.00%	-539.88%	-	-
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-100.00%	-33.76%	-33.76%	-33.76%	-	-	-	-	-	-
Net Income Growth (1Y)	-14.29%	-44.64%	-17.37%	-16.71%	-16.37%	2.39%	-43.26%	-37.32%	-31.69%	-9.08%	23.44%	19.92%
EPS Growth (1Y)	-13.49%	-43.52%	-18.27%	-17.90%	-17.48%	1.28%	-47.78%	-37.75%	-41.55%	-23.98%	-0.25%	-3.52%
Valuation Metrics
P/E TTM	-2.48	-1.32	-0.71	-0.73	-0.51	-0.51	-1.30	-1.46	-1.49	-5.10	-3.39	-4.95
P/B TTM	2.41	0.90	0.45	0.43	0.30	0.39	0.64	0.74	0.76	2.44	2.27	2.94
P/S TTM	-	-	-	4.05	3.11	4.24	3.19	6.45	7.16	27.55	-	-
Market Cap	345.93M	164.42M	97.02M	108.93M	83.51M	113.97M	215.37M	261.69M	290.55M	1.12B	990.95M	1.42B
Enterprise Value	318.52M	129.86M	58.40M	67.23M	43.28M	69.41M	178.84M	217.74M	250.90M	1.08B	962.91M	1.30B
Calculated Values
Free Cash Flow TTM	-127.84M	-125.60M	-125.25M	-153.78M	-170.43M	-151.70M	-171.08M	-85.04M	-114.89M	-211.14M	-208.41M	-205.12M
Net Debt	-27.41M	-34.56M	-38.62M	-41.70M	-40.23M	-44.56M	-36.53M	-43.95M	-39.66M	-40.30M	-28.04M	-113.38M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-10Sale

Owner: Vultaggio, Vincent

Title: PAO and PFO

Shares: 6,894

Price/Share: $2.42

Value: $16,683.48

Shares Owned: 146,506

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Eastland, Julia Marie

Title: CEO & President

Shares: 889

Price/Share: $2.39

Value: $2,124.71

Shares Owned: 79,133

Relationship: Director,Officer

Ownership: Direct

2026-02-09Sale

Owner: Bruns, Ingmar

Title: Chief Medical Officer

Shares: 335

Price/Share: $2.39

Value: $800.65

Shares Owned: 33,332

Relationship: Officer

Ownership: Direct

2026-02-03Sale

Owner: Vultaggio, Vincent

Title: PAO and PFO

Shares: 556

Price/Share: $2.52

Value: $1,401.12

Shares Owned: 186,730

Relationship: Officer

Ownership: Direct

2025-12-31Purchase

Owner: Walters, William Thurman,…

Title: -

Shares: 6,459,973

Price/Share: $1.20

Value: $7,751,967.60

Shares Owned: 13,509,973

Relationship: TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-10	Vultaggio, Vincent	Officer	PAO and PFO	Direct	Sale	6,894	2.42	$16,683.48	146,506	4
2026-02-09	Eastland, Julia Marie	Director,Officer	CEO & President	Direct	Sale	889	2.39	$2,124.71	79,133	4
2026-02-09	Bruns, Ingmar	Officer	Chief Medical Officer	Direct	Sale	335	2.39	$800.65	33,332	4
2026-02-03	Vultaggio, Vincent	Officer	PAO and PFO	Direct	Sale	556	2.52	$1,401.12	186,730	4
2025-12-31	Walters, William Thurman,…	TenPercentOwner	-	Direct	Purchase	6,459,973	1.20	$7,751,967.60	13,509,973	4
2025-12-15	Goel, David E., Matrix Ca…	TenPercentOwner	-	Indirect	Sale	7,500,000	1.33	$9,975,000.00	6,459,973	4
2025-04-30	Myers, Scott Dunseth	Director	-	Direct	Purchase	21,000	1.40	$29,400.00	281,192	4
2025-02-06	Bruns, Ingmar	Officer	Chief Medical Officer	Direct	Purchase	20,000	2.28	$45,600.00	36,629	4
2025-02-03	Paul, Andrea	Officer	Chief Legal Officer	Direct	Sale	13,230	1.71	$22,623.30	1,070,784	4
2025-02-03	Vultaggio, Vincent	Officer	PAO and Interim PFO	Direct	Sale	2,615	1.71	$4,471.65	189,826	4
2025-02-03	Lackner, Mark	Officer	Chief Scientific Officer	Direct	Sale	14,368	1.71	$24,569.28	512,856	4
2025-01-31	Skvarka, Jan	Director	-	Direct	Purchase	60,000	1.72	$103,200.00	149,551	4
2025-01-31	Eastland, Julia Marie	Director,Officer	CEO & President	Direct	Purchase	28,500	1.73	$49,305.00	28,500	4
2025-01-31	Walker, Luke Nathaniel	Director	-	Direct	Purchase	14,200	1.76	$24,992.00	86,681	4
2025-01-02	Lackner, Mark	Officer	Chief Scientific Officer	Direct	Sale	4,411	3.12	$13,762.32	191,317	4
2024-10-04	Vultaggio, Vincent	Officer	Principal Accounting Officer	Direct	Sale	1,603	3.18	$5,097.54	33,855	4
2024-05-31	Gallagher, Cam	Director,Officer	President, Interim CFO	Direct	Sale	9,597	11.98	$114,972.06	633,680	4
2024-05-09	Hausman, Diana	Officer	Chief Medical Officer	Direct	Sale	3,356	12.62	$42,352.72	373,876	4
2024-02-12	Epperly, Melissa B,	Officer	Chief Financial Officer	Direct	Sale	2,573	11.44	$29,435.12	451,449	4
2024-02-12	Gallagher, Cam	Director,Officer	President	Direct	Sale	1,173	11.44	$13,419.12	643,277	4
2024-02-02	Paul, Andrea	Officer	Chief Legal Officer	Direct	Sale	3,310	11.54	$38,197.40	149,973	4
2024-02-02	Lackner, Mark	Officer	Chief Scientific Officer	Direct	Sale	1,585	11.54	$18,290.90	195,728	4
2024-02-02	Gallagher, Cam	Director,Officer	President	Direct	Sale	11,552	11.54	$133,310.08	644,450	4
2024-02-02	Epperly, Melissa B,	Officer	Chief Financial Officer	Direct	Sale	8,669	11.54	$100,040.26	454,022	4
2023-11-13	Blackwell, Kimberly	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	10.29	$51,450.00	254,800	4
2023-11-10	Johnson, David Michael	Director	-	Direct	Purchase	17,000	9.88	$167,960.00	144,389	4
2023-10-04	Brownstein, Carrie	Officer	Chief Medical Officer	Direct	Sale	10,628	19.67	$209,052.76	105,685	4
2023-10-04	Epperly, Melissa B,	Officer	Chief Financial Officer	Direct	Sale	5,482	19.67	$107,830.94	387,691	4
2023-10-04	Bunker, Kevin D.	Officer	Chief Scientific Officer	Direct	Sale	6,068	19.67	$119,357.56	859,089	4
2023-09-11	Skvarka, Jan	Director	-	Direct	Sale	5,000	25.05	$125,250.00	47,970	4
2023-06-20	Matrix, Capital Managemen…	TenPercentOwner	-	Indirect	Purchase	4,760,000	22.66	$107,861,600.00	13,959,973	4
2023-05-31	Gallagher, Cam	Director,Officer	President	Direct	Sale	27,768	26.30	$730,298.40	463,502	4
2023-05-26	Bunker, Kevin D.	Officer	Chief Scientific Officer	Indirect	Sale	80,000	30.02	$2,401,600.00	15,000	4
2023-02-14	Gallagher, Cam	Director,Officer	President	Direct	Sale	8,501	19.96	$169,679.96	491,270	4
2023-02-14	Bunker, Kevin D.	Officer	Chief Scientific Officer	Direct	Sale	6,500	19.98	$129,870.00	865,157	4
2023-02-14	Epperly, Melissa B,	Officer	Chief Financial Officer	Direct	Sale	5,227	19.98	$104,435.46	392,048	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

56.78%

Inst. Shares: 39,894,587

Shares Outstanding: 70,264,000

2025-12-31

50.76%

Inst. Shares: 36,482,856

Shares Outstanding: 71,869,000

2025-09-30

67.41%

Inst. Shares: 48,630,016

Shares Outstanding: 72,139,000

2025-06-30

71.32%

Inst. Shares: 51,343,566

Shares Outstanding: 71,992,000

2025-03-31

76.12%

Inst. Shares: 54,564,096

Shares Outstanding: 71,678,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	39,894,587	70,264,000	56.78%
2025-12-31	36,482,856	71,869,000	50.76%
2025-09-30	48,630,016	72,139,000	67.41%
2025-06-30	51,343,566	71,992,000	71.32%
2025-03-31	54,564,096	71,678,000	76.12%
2024-12-31	61,445,538	71,080,000	86.45%
2024-09-30	68,628,804	71,111,000	96.51%
2024-06-30	73,812,517	71,040,000	103.90%
2024-03-31	77,647,221	70,898,000	109.52%
2023-12-31	74,910,155	65,409,000	114.53%
2023-09-30	74,608,477	70,612,000	105.66%
2023-06-30	76,494,184	60,790,000	125.83%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Zentalis Pharmaceuticals, Inc. (ZNTL) — SEC Financial Statements & Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL) is a pharmaceutical preparations company. Zentalis Pharmaceuticals, Inc. trades on Nasdaq as: ZNTL. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Zentalis Pharmaceuticals, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.50x, a Price-to-Sales (P/S) ratio of 4.05x (TTM), a Price-to-Book (P/B) ratio of 2.41x (TTM), at a market cap of $345.93M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.50x
P/S TTM: 4.05x
P/B TTM: 2.41x
Market Cap: $345.93M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Zentalis Pharmaceuticals, Inc. in?

Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Pharmaceutical Preparations industry.

What is ZNTL's market cap?

Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $345.93M as of 2026-06-30.

What exchange does ZNTL trade on?

Zentalis Pharmaceuticals, Inc. (ZNTL) trades on the Nasdaq.